Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;370(1):41-46.
doi: 10.1016/j.amjms.2025.03.008. Epub 2025 Mar 12.

Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias

Ahmed Ibrahim  1 , Jad Allam  1 , Don C Rockey  2
Affiliations

Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias

Ahmed Ibrahim et al. Am J Med Sci. 2025 Jul.

Abstract

Background: Angiodysplasias commonly develop in patients with left ventricular assist devices (LVADs) and often bleed recurrently. Whether octreotide reduces the burden of angiodysplasia or the frequency of bleeding in these patients is controversial. Hence, we aimed to study the effect of long-acting octreotide on angiodysplasia bleeding in LVAD patients.

Methods: Between May 2012 and December 2023, 65 patients with LVAD and angiodysplasia were identified at our tertiary care medical center. Of those, 33 patients received octreotide therapy. Complete clinical data were abstracted from the medical record, and outcomes pre and post octreotide therapy were examined.

Results: In 33 patients (61 ± 8 years old and 9 women) who received long-acting octreotide for recurrent angiodysplasia bleeding that failed to respond to endoscopic therapy, the small intestine was the most common site involved. Prior to octreotide, patients received an average of 2.0 ± 3.0 units/month of PRBCs over an average of 16 months, which decreased to 0.5 ± 0.8 units/month over 31 months on therapy. Over an average period of 31 months on octreotide therapy, GI bleeding events and the number of endoscopic therapies per month decreased from 0.4 ± 0.2 to 0.1 ± 0.2 (p = 0.01) and from 0.7 ± 0.8 to 0.1 ± 0.2 (p = 0.001), respectively. Finally, hemoglobin and hematocrit levels increased over the 31 month follow-up period while on octreotide therapy.

Conclusion: In patients with an LVAD and recurrent angiodysplasia bleeding, octreotide appeared to reduce the number of GI bleeding events, the need for GI endoscopic therapies, and the frequency of PRBC transfusions.

Keywords: Endoscopy; Gastrointestinal; Hemorrhage; Small bowel; Stomach.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest All authors declare that they have no conflict of interest pertaining to the study.

References

    1. Brock AS, Cook JL, Ranney N, et al. Clinical problem-solving. A not-so-obscure cause of gastrointestinal bleeding. N Engl J Med 2015;372(6):556–61. - PubMed
    1. Blackshear JL, McRee CW, Safford RE, et al. von Willebrand factor abnormalities and Heyde syndrome in dysfunctional heart valve prostheses. JAMA Cardiol 2016;1(2):198–204. - PubMed
    1. Molina EJ, Shah P, Kiernan MS, et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg 2021;111(3):778–792. - PubMed
    1. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56(15):1207–13. - PubMed
    1. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003;349(4):343–9. - PubMed